Last year, Duke became the first institution in North Carolina to offer lecanemab, the first drug targeting the underlying processes of Alzheimer’s disease that has shown a clinical benefit. Duke now conducts the largest lecanemab clinic in the state, giving early-stage Alzheimer’s patients the gift of time and raising awareness about the need for more research.
Read Full Story